JP2010515707A - Dbaitおよびその単独使用 - Google Patents
Dbaitおよびその単独使用 Download PDFInfo
- Publication number
- JP2010515707A JP2010515707A JP2009545182A JP2009545182A JP2010515707A JP 2010515707 A JP2010515707 A JP 2010515707A JP 2009545182 A JP2009545182 A JP 2009545182A JP 2009545182 A JP2009545182 A JP 2009545182A JP 2010515707 A JP2010515707 A JP 2010515707A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- molecule
- dbait32hc
- use according
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 23
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 23
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 230000033616 DNA repair Effects 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 74
- 238000011282 treatment Methods 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 52
- 102100034533 Histone H2AX Human genes 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 101710195517 Histone H2AX Proteins 0.000 claims description 22
- 230000026731 phosphorylation Effects 0.000 claims description 22
- 238000006366 phosphorylation reaction Methods 0.000 claims description 22
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 claims description 21
- 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 claims description 21
- 230000005778 DNA damage Effects 0.000 claims description 20
- 231100000277 DNA damage Toxicity 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 230000002062 proliferating effect Effects 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 150000004713 phosphodiesters Chemical group 0.000 claims description 9
- 102000015335 Ku Autoantigen Human genes 0.000 claims description 8
- 108010025026 Ku Autoantigen Proteins 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 238000009739 binding Methods 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 6
- 125000003636 chemical group Chemical group 0.000 claims description 6
- 230000002601 intratumoral effect Effects 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 230000004543 DNA replication Effects 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical group OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 claims description 3
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 3
- -1 morpholino nucleic acid Chemical class 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- 229930024421 Adenine Natural products 0.000 claims description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 108060002716 Exonuclease Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 229960000643 adenine Drugs 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 210000003855 cell nucleus Anatomy 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 229940104302 cytosine Drugs 0.000 claims description 2
- 102000013165 exonuclease Human genes 0.000 claims description 2
- 125000003827 glycol group Chemical group 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 claims description 2
- 150000002430 hydrocarbons Chemical group 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229940113082 thymine Drugs 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 230000005782 double-strand break Effects 0.000 abstract description 23
- 230000037361 pathway Effects 0.000 abstract description 22
- 230000008439 repair process Effects 0.000 abstract description 15
- 230000006780 non-homologous end joining Effects 0.000 abstract description 14
- 210000004881 tumor cell Anatomy 0.000 abstract description 10
- 238000001514 detection method Methods 0.000 abstract description 6
- 210000004962 mammalian cell Anatomy 0.000 abstract description 5
- 230000019491 signal transduction Effects 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 230000034994 death Effects 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 19
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 11
- 238000011580 nude mouse model Methods 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 8
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 7
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 102100036973 X-ray repair cross-complementing protein 5 Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 238000002689 xenotransplantation Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 101710124921 X-ray repair cross-complementing protein 5 Proteins 0.000 description 4
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 4
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 4
- 230000022534 cell killing Effects 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 1
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101150059802 KU80 gene Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000000648 angioblast Anatomy 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000001818 capillary gel electrophoresis Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000003674 kinase activity assay Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000006335 response to radiation Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
放射線治療および化学治療は、単独または外科手術との併用で、ヒトの癌に対する必須の治療兵器である。化学治療と放射線治療の間の関連性は癌処置において広く使用された。依然として完全には解明されていないが、細胞毒性作用の生物学的基礎は、細胞周期またはDNA損傷などの細胞機構に依存しており、それは放射線誘発性の細胞死においても重要であり、癌治療において異なる処置を併用することにより、付加的な、またはさらには相乗的な利点をもたらす。
1)PI3K(ホスファチジルイノシトール−3−キナーゼ)の阻害剤(すなわち、DNA−PKcs、ATM、ATR)(Bouton et al., 2000; Durant & Karran, 2003; Willmore et al., 2004; Yauger et al., 2004);
2)ネガティブドミナント&ペプチド(KU80のC末端)(Marangoni et al., 2000b; Kim et al., 2002);
3)一本鎖抗体可変フラグメント(scFv)(DNA−PKcs)(Li et al., 2003a);
4)RNAアプタマー(SELEX:RNA結合Ku)(Yoo & Dynan, 1998);
5)アンチセンス(Ku70、Ku80、DNA−PKcs)(Li et al., 2003b; Marangoni et al., 2000c; Sak et al., 2002);
6)siRNA(DNA−PKcs)(Peng et al., 2000)。
発明者らは、驚くべきことに、任意の直接的または間接的なDNA損傷処置(すなわち、化学治療、放射線治療)の非存在下において、腫瘍細胞がDbait分子単独の存在に対して感受性であることを見出した。実施例において示すとおり、Dbait分子は、単独の癌処置として使用するために、インビトロならびにインビボで効果的である。
1)二本鎖Dbait分子は薬学的に許容される担体/賦形剤と使用した場合、細胞/組織体により細胞核に取り込ませることができる;
2)Dbaitの少なくとも1つの自由末端は、DSB損傷検知、シグナル伝達、および/または修復工程に関与する酵素のホロ複合体により認識可能である;および
3)Dbait分子の少なくとも1つの自由末端は、前記の複合体により受け入れられて、腫瘍細胞のゲノムDNA中に取り入れられる。
Dbait分子は特許出願国際公開第2005/040378号において完全に記載されたが、明確さのために、Dbait分子の設計、合成、および調製を実施例1においてまとめる。
2種類のDbait分子を設計した:直線状またはヘアピンdsDNAフラグメント。ヘアピンDbait分子のために、ヘキサエチレングリコールリンカーまたはテトラデオキシチミジル酸をループとして使用した。
二分子Dbait分子(Dbait32、Dbait32−NH2、Dbait64、およびDbait64L)について:
再蒸留水中の各鎖の1:1原液(好ましくは高濃度)の混合物を、各鎖の完全な変性のために90℃で5分間加熱する必要がある。アニーリングは室温に円滑に戻すことにより実施し(サンプルは典型的に水浴中に放置する)、結果として得られる二本鎖分子を一定分量で、−20℃で保存した。
再蒸留水において200μMのヘアピンDbait分子を含む溶液を、完全な変性のために90℃で5分間加熱する必要がある。アニーリングは、サンプルを氷水(0℃)中で冷却することにより実施する必要がある。一定分量の保存は20℃であった。
特許出願国際公開第2005/040378号は、細胞抽出物の存在下において、および、任意のDNA損傷処置の非存在下において以下の証拠を提供する:
1)Dbait分子は、NHEJ経路の第1工程に関与するKuタンパク質のためのベイトである;
2)Dbait分子は、DNA末端結合反応の競合分子であるが、しかし、結合した複合体を置換しない。Kuタンパク質の動員は必要条件である;
3)32bp長のDbait分子はDNA−PKを活性化できる。簡単な無細胞DNA−PK活性アッセイによって、その配列および化学修飾にある程度関係なく、Dbait分子の長さ(約32bp)および自由末端を伴う二本鎖DNAのみがキナーゼ活性化のために必要とされることが指摘される。これは、NHEJ経路におけるDNA−PKcs、配列非依存的なDNA末端結合メカニズムの意味と一致する。
新しい分子治療としてのDbait分子のインビボ活性、すなわち、従来のDNA損傷治療の代替物は、放射線耐性細胞株の皮下注射によりヒト腫瘍で異種移植したヌードマウスを使用して評価した(ヒト頭頸部扁平上皮癌由来のHep2、HNSCC;ならびにヒトメラノーマ由来のLU1205およびSK28)。
注入が静脈内または皮下を問わず、任意のサイトカインの有意な誘導はDbait32Hcで検出されなかった。発明者らは、Balb/CマウスにおけるDbait32Hcの静脈内(IV)または皮下(SC)注入後の免疫応答を評価する。血液サンプルにおいてIL2、IL4、IL5、IL6、IL10、IL12P70、IFNγ、およびTNFαのレベルを、Dbaitの反復注入後の様々な時間に測定した。動物は、毒性徴候または皮膚炎症を発症することなく、24日間以内に120mg(9nmol)のDbaitでの7回の注射を受けた。発明者らは、免疫原性のCpG配列を含まないDbait32Hcと4つのCpGを含むDbait32Hに対する免疫応答を比較した。唯一、Dbait32HがIL6の迅速な応答およびIL12p70のより遅延型の応答を誘導した(図8)。
Claims (23)
- 任意の直接的または間接的なDNA損傷処置の非存在下において増殖性疾患を処置するための薬剤を調製するための核酸分子の使用であって、該核酸分子が、少なくとも16bp、好ましくは26bp超、より好ましくは32bp超の二本鎖部分を含み、少なくとも1つの自由末端を有し、および、該分子が、少なくともKuタンパク質による結合のための基質であり、DNA−PKcsを活性化できる、使用。
- 該分子が、16〜200bp、最も好ましくは32〜100bpを含む、請求項1記載の使用。
- 該分子が、直線状またはヘアピン核酸分子である、請求項1または2記載の使用。
- 該分子が、ヘアピン核酸分子であり、該ループが核酸または化学基を含む、請求項3記載の使用。
- 該自由末端が、平滑または5’または3’突出である、請求項1〜4のいずれか一項記載の使用。
- 該分子が、ヒストンH2AXのリン酸化を増加する、請求項1〜5のいずれか一項記載の使用。
- 該分子が、細胞により細胞核内に取り込まれることができる、請求項1〜6のいずれか一項記載の使用。
- 該分子が、ホスホジエステル骨格または化学修飾したホスホジエステル骨格または1もしくは数個の化学基を有する別の骨格を含む、請求項1〜7のいずれか一項記載の使用。
- 該分子が、2’−デオキシヌクレオチド骨格を含み、および場合により1または数個の修飾ヌクレオチドおよび/またはアデニン、シトシン、グアニンおよびチミン以外の核酸塩基を含む、請求項1〜7のいずれか一項記載の使用。
- 該骨格が、メチルホスホネート、ホスホルアミデート、モルホリノ核酸、2’−0,4’−Cメチレン/エチレン架橋ロックド核酸、ペプチド核酸(PNA)、短鎖アルキル、またはシクロアルキル糖間結合または可変長の短鎖ヘテロ原子または複素環の糖間結合を含む、請求項8または9記載の使用。
- ペントフラノシル基の代わりに、2’−O−アルキルリボース、2’−O−アルキル−C4’分岐リボース、シクロブチル、もしくは他の炭素環などの糖模倣体またはヘキシトールをさらに含む、請求項8または9記載の使用。
- 各鎖の末端または少なくとも3’末端鎖に1または数個の化学修飾したヌクレオチドを含む、請求項1〜11のいずれか一項記載の使用。
- 各鎖の末端または少なくとも3’末端鎖に1または数個のホスホロチオエートを含む、請求項12記載の使用。
- 少なくとも1つの埋め込みエレメントをさらに含み、それによってDNA複製、DNA修復、または損傷シグナル伝達過程が妨げられ、該少なくとも1つのエレメントは、二本鎖分子の中央または末端に組み入れられる、請求項1〜13のいずれか一項記載の使用。
- a)ポリエチレングリコール鎖、好ましくはヘキサエチレングリコール鎖、または場合により1または複数のヘテロ原子、例えば酸素、硫黄、窒素、または1または数個のヘテロ原子を含む、ヘテロ原子基または複素環基により中断および/または置換された、任意の炭化水素鎖;および/または
b)任意の3’修飾ヌクレオチドなどの、DNAポリメラーゼまたはエクソヌクレアーゼにより受け入れられないことから遮断エレメントであるユニット;および/または
c)Tnなどの天然オリゴヌクレオチド、ヘアピンフラグメントのループにおいて使用されるとき、好ましくはテトラデオキシチミジレート(T4)
を含む、請求項14記載の使用。 - 該分子が、Dbait32(配列番号1)、Dbait32Ha(配列番号28)、Dbait32Hb(配列番号29)、Dbait32Hc(配列番号30)、またはDbait32Hd(配列番号31)と同じヌクレオチド組成を含む少なくとも32bpまたは32bpの二本鎖部分を有する、請求項1〜15のいずれか一項記載の使用。
- 該分子が、Dbait32(配列番号1)、Dbait32H−po(配列番号3)、Dbait32H(配列番号4)、Dbait32−T4(配列番号2)、Dbait32Hc−5’5’(配列番号14)、Dbait32−NH2(配列番号15)、Dbait32H−FITC(配列番号21)、Dbait32H−Cy3(配列番号22)、Dbait32H−Biot(配列番号23)、Dbait32Ha(配列番号8)、Dbait32Hb(配列番号9)、Dbait32Hc(配列番号10)、Dbait32Hd(配列番号11)、Dbait32Hc−3’mp(配列番号12)、Dbait32Hc−5’3’mp(配列番号13)、Dbait32Hc−Cy3(配列番号25)、Dbait32Hc−Cy5(配列番号26)、Dbait32Hd−FITC(配列番号27)、Dbait32Ha ds(配列番号28)、Dbait32Hb ds(配列番号29)、Dbait32Hc ds(配列番号30)、Dbait32Hd ds(配列番号31)、Dbait64(配列番号19)、およびDbait64L(配列番号20)からなる群より選択される、請求項16記載の使用。
- 該分子の該二本鎖部分が、Dbait32(配列番号1)、Dbait32Ha(配列番号28)、Dbait32Hb(配列番号29)、Dbait32Hc(配列番号30)、またはDbait32Hd(配列番号31)の少なくとも16、18、20、22、24、26、28、30または32の連続ヌクレオチドを含む、請求項1〜15のいずれか一項記載の使用。
- 該増殖性疾患が、好ましくは、膠芽腫、頭頚部癌、大腸癌、肝臓癌、肺癌、皮膚癌、乳癌および子宮頸癌から選択される癌である、請求項1〜18のいずれか一項記載の使用。
- 該分子が、経口経路により、または静脈内、腫瘍内、もしくは皮下注入、頭蓋内もしくは動脈内注射もしくは注入により、または経口経路により投与される、請求項1〜19のいずれか一項記載の使用。
- 該分子が、毎日の処置プロトコールにおいて、少なくとも0.1mg/cm3腫瘍、好ましくは0.6mg/cm3腫瘍、最も好ましくは1mg/cm3腫瘍、または、毎週の処置プロトコールにおいて、少なくとも0.3mg/cm3腫瘍、好ましくは1.8mg/cm3腫瘍、最も好ましくは3mg/cm3腫瘍の有効量での腫瘍内投与により使用される、請求項1〜20のいずれか一項記載の使用。
- ヒストンH2AXのリン酸化を測定することを含む、請求項1〜19のいずれか一項記載の核酸による処置の効率を評価するための方法。
- 該細胞および/または組織に請求項1〜19のいずれか一項記載の核酸を導入することを含む、細胞および/または組織においてヒストンH2AXのリン酸化を増加するため、または、ヒストンH2AXを活性化するための方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07300728A EP1944369A1 (en) | 2007-01-12 | 2007-01-12 | Dbait and its standalone uses thereof |
EP07300728.8 | 2007-01-12 | ||
PCT/EP2008/050265 WO2008084087A2 (en) | 2007-01-12 | 2008-01-11 | Dbait and its standalone uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010515707A true JP2010515707A (ja) | 2010-05-13 |
JP2010515707A5 JP2010515707A5 (ja) | 2011-02-17 |
JP5462632B2 JP5462632B2 (ja) | 2014-04-02 |
Family
ID=38515555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009545182A Active JP5462632B2 (ja) | 2007-01-12 | 2008-01-11 | Dbaitおよびその単独使用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8093366B2 (ja) |
EP (2) | EP1944369A1 (ja) |
JP (1) | JP5462632B2 (ja) |
CN (1) | CN101622351B (ja) |
AU (1) | AU2008204486C1 (ja) |
CA (1) | CA2673972C (ja) |
EA (1) | EA016053B1 (ja) |
WO (1) | WO2008084087A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013534521A (ja) * | 2010-06-22 | 2013-09-05 | デエヌア・テラプーティック | 核酸コンジュゲートのためのエンドソーム溶解剤を用いた最適化invivo送達システム |
JP2021515580A (ja) * | 2018-03-13 | 2021-06-24 | オンクセオOnxeo | がんの治療における獲得耐性に対抗するdbait分子 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015202211B2 (en) * | 2010-06-22 | 2016-09-01 | Centre National De La Recherche Scientifique | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
EP2527440A1 (en) * | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
CN108138177B9 (zh) | 2015-07-23 | 2021-08-13 | 法国居里学院 | Dbait分子与PARP抑制剂的组合用于治疗癌症的用途 |
US10821128B2 (en) * | 2016-03-01 | 2020-11-03 | Onxeo | Treatment of cancer by systemic administration of Dbait molecules |
WO2017186882A1 (en) * | 2016-04-29 | 2017-11-02 | Onxeo | A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2018231752A1 (en) * | 2017-06-12 | 2018-12-20 | University Of Miami | Sting-dependent activators for treatment of disease |
CN107793468A (zh) * | 2017-06-26 | 2018-03-13 | 上海悦良生物科技有限公司 | 一种检测dna损伤的方法 |
EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
CN109321585B (zh) * | 2018-09-30 | 2021-08-06 | 山东大学 | 一种利用t4脱氧核糖核酸连接酶提高原核微生物诱变育种效率的方法 |
EP3898974A1 (en) | 2018-12-21 | 2021-10-27 | Onxeo | New conjugated nucleic acid molecules and their uses |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021178295A1 (en) * | 2020-03-03 | 2021-09-10 | University Of Washington | Synthetic agonists of dna-pk and their use |
US11897888B1 (en) | 2020-04-30 | 2024-02-13 | Stinginn Llc | Small molecular inhibitors of sting signaling compositions and methods of use |
TW202210633A (zh) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
WO2023111203A1 (en) | 2021-12-16 | 2023-06-22 | Onxeo | New conjugated nucleic acid molecules and their uses |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005040378A1 (en) * | 2003-10-24 | 2005-05-06 | Institut Curie | Nucleic acids useful for triggering tumor cell lethality |
JP2005247807A (ja) * | 2004-03-08 | 2005-09-15 | Japan Science & Technology Agency | Nsaidを利用した癌治療用組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060276423A1 (en) * | 2005-04-18 | 2006-12-07 | Rachel Altura | Survivin-directed RNA interference-compositions and methods |
-
2007
- 2007-01-12 EP EP07300728A patent/EP1944369A1/en not_active Withdrawn
-
2008
- 2008-01-11 AU AU2008204486A patent/AU2008204486C1/en active Active
- 2008-01-11 CN CN200880002041.7A patent/CN101622351B/zh active Active
- 2008-01-11 CA CA2673972A patent/CA2673972C/en active Active
- 2008-01-11 EA EA200900989A patent/EA016053B1/ru not_active IP Right Cessation
- 2008-01-11 WO PCT/EP2008/050265 patent/WO2008084087A2/en active Application Filing
- 2008-01-11 US US12/520,961 patent/US8093366B2/en active Active
- 2008-01-11 JP JP2009545182A patent/JP5462632B2/ja active Active
- 2008-01-11 EP EP08701411.4A patent/EP2102343B1/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005040378A1 (en) * | 2003-10-24 | 2005-05-06 | Institut Curie | Nucleic acids useful for triggering tumor cell lethality |
JP2005247807A (ja) * | 2004-03-08 | 2005-09-15 | Japan Science & Technology Agency | Nsaidを利用した癌治療用組成物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013534521A (ja) * | 2010-06-22 | 2013-09-05 | デエヌア・テラプーティック | 核酸コンジュゲートのためのエンドソーム溶解剤を用いた最適化invivo送達システム |
JP2021515580A (ja) * | 2018-03-13 | 2021-06-24 | オンクセオOnxeo | がんの治療における獲得耐性に対抗するdbait分子 |
Also Published As
Publication number | Publication date |
---|---|
CA2673972C (en) | 2016-03-22 |
EA016053B1 (ru) | 2012-01-30 |
EP2102343B1 (en) | 2015-07-08 |
JP5462632B2 (ja) | 2014-04-02 |
EP2102343A2 (en) | 2009-09-23 |
AU2008204486A1 (en) | 2008-07-17 |
CN101622351B (zh) | 2014-05-14 |
EA200900989A1 (ru) | 2009-12-30 |
WO2008084087A3 (en) | 2009-01-08 |
AU2008204486B2 (en) | 2012-11-29 |
CN101622351A (zh) | 2010-01-06 |
AU2008204486C1 (en) | 2013-05-16 |
US20100022622A1 (en) | 2010-01-28 |
EP1944369A1 (en) | 2008-07-16 |
CA2673972A1 (en) | 2008-07-17 |
US8093366B2 (en) | 2012-01-10 |
EP1944369A9 (en) | 2008-10-15 |
WO2008084087A2 (en) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5462632B2 (ja) | Dbaitおよびその単独使用 | |
JP5415952B2 (ja) | Dbaitおよびその使用 | |
JP5662822B2 (ja) | 腫瘍細胞致死性をトリガーするのに有用な核酸 | |
KR102441432B1 (ko) | Dbait 분자의 전신 투여에 의한 암 치료법 | |
CN110177877A (zh) | 反义寡核苷酸 | |
AU2007298990B8 (en) | Dbait and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101222 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130618 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130905 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131202 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131224 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140117 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5462632 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |